

Speaker Biographies



Dr. David Cooper

David Cooper AO, Scientia Professor of Medicine at the University of New South Wales and a Fellow of the Australian Academy of Science (FAA), is Director of the National Centre in HIV Epidemiology and Clinical Research, Sydney, Australia. The National Centre is funded by the Australian Government Department of Health and Ageing, to conduct research into the HIV/AIDS epidemic in Australia with the ultimate aim of reducing the burden of the HIV/AIDS epidemic for the affected community.

The major responsibilities of the National Centre are the epidemiology and surveillance of HIV/AIDS in Australia, including research aspects and the coordination and conduct of clinical trials of innovative therapies and vaccines for HIV disease, as well as an active clinical research program with particular emphasis on HIV infection and viral hepatitis and sexually transmitted infections.

In addition to the National Centre, Professor Cooper is Head of the Immunology/HIV/Infectious Diseases Clinical Service Unit at St Vincent's Hospital, Sydney, one of the largest inpatient and outpatient services for the treatment of HIV disease in Australia. He is co-Director of the St Vincent's Hospital Medical Research groups. Professor Cooper is an author on over 400 published scientific papers and is on the editorial boards of several international journals.

Internationally, Professor Cooper is recognised as a leading HIV clinician and clinical investigator. He is a past President of the International AIDS Society and a fellow of the Australian Academy of Science. He is a Director of HIVNAT, a clinical research and trials collaboration based at the Thai Red Cross AIDS Research Centre at the Chulalongkorn University Hospital in Bangkok, Thailand. He is actively involved in studies of biomedical prevention strategies for HIV infection in the developing world including vaccines and chemoprophylaxis.

Professor Cooper is married to Dorrie and has two daughters, Rebecca and Ilana.

e-mail: dcooper@nchecr.unsw.edu.au

telephone: +61 (2) 9385 0930

People Living With HIV/AIDS NSW

People Living With HIV/AIDS New South Wales is a non profit community organisation representing the interests of people living with HIV/AIDS in New South Wales. Incorporated on 21st July 1989 it is partially funded by the government and is dependent on donations. An executive officer manages the organization in conjunction with an elected board of eight and one staff representative.

People Living With HIV/AIDS New South Wales works to promote a positive image of people affected by HIV/AIDS with the aim of eliminating prejudice, isolation, stigmatisation and discrimination.

The aims and objectives of PLWHA NSW are:

- *To empower people living with HIV/AIDS in New South Wales with information, referral and advice on all relevant issues; in particular health promotion information and matters dealing with life issues*
- *To advocate on behalf of people living with HIV/AIDS and lobby government, business and non-government organisations about issues of concern to people living with HIV/AIDS, with the aim of ensuring optimum wellbeing, care and support for people living with HIV/AIDS, their partners, family members and significant others.*
- *To promote a positive image of people living with and affected by HIV/AIDS, with the aim of eliminating prejudice, isolation, stigmatisation and discrimination.*
- *To work closely with the HIV specific and mainstream health and community sectors and other relevant organisations in the pursuit of these objectives.*
- *To receive donations, grants and bequests from persons and institutions including governments and to engage in such fundraising activities as may achieve the objectives of the Association.*

e-mail: RobL@plwha.org.au

telephone: (02) 9361 6011

Professor Andrew Grulich

Andrew Grulich is Professor of Epidemiology and Head of the HIV Epidemiology and Prevention Program at the National Centre in HIV Epidemiology and Clinical Research at the University of New South Wales, in Sydney.

He is a past President of the Australasian Society for HIV Medicine and sits on the editorial board of several peer-reviewed journals including *AIDS* and *Sexual Health*. He is Chair of the ministerial advisory committee on AIDS in New South Wales, and has sat on the Australian Federal Health minister's HIV advisory committee for more than 5 years.

Andrew's research interests include the transmission and prevention of HIV infection, including the role of male circumcision, exposure prophylaxis, interventions targeted against sexually transmissible infections, and HIV-associated cancers. He has contributed to more than 150 peer-reviewed publications.

e-mail: agrulich@nchechr.unsw.edu.au

telephone: +61 2 9385 0956

Sam Avrett

As of June 2007, Sam Avrett has joined the Foundation for AIDS Research (amfAR) to lead the new MSM Initiative being launched by amfAR at the 4th IAS Conference on Pathogenesis, Treatment, and Prevention in Sydney, Australia.

Sam Avrett has worked since 1987 to support community-based HIV/AIDS prevention and treatment efforts, beginning with volunteer HIV prevention outreach projects targeting injection drug users and male sex workers in Washington DC.

On the topic of HIV vaccine development, beginning in 1995, Sam was a founding Board member and first Executive Director of the AIDS Vaccine Advocacy Coalition (AVAC) and a former Associate Scientific Director of the International AIDS Vaccine Initiative (IAVI). Previously, Sam worked as the project director for the New York Blood Center to manage a multi-site HIV epidemiology and vaccine feasibility study among men who have sex with men (MSM) and at-risk women in New York City.

In the field of microbicide development, Sam has recently worked as the writer of the publication *Microbicide Watch 2006*, produced by the Alliance for Microbicide Development, and was final editor of the *Microbicide Development Strategy*, a document produced through the collaborative efforts of more than 100 experts in the field.

In 2001, Sam consulted with UNAIDS to support civil society participation and perspectives in the first United Nations General Assembly Special Session on HIV/AIDS (UNGASS). Sam has worked as a consultant to global organizations such as the International AIDS Society (IAS), the International Council of AIDS Service Organizations (ICASO), the International Treatment Preparedness Coalition (ITPC), and the WHO-UNAIDS HIV Vaccine Initiative. Sam has also been a consultant and ally for AIDS advocacy organizations such as the Canadian HIV/AIDS Legal Network, the AIDS Rights Alliance of Southern Africa (ARASA), and Treatment Action Campaign (TAC).

Sam Avrett is a gay man, openly HIV-positive, living with his partner in a rural farming community in New York State. Sam volunteers as a Board member of the AIDS Vaccine Advocacy Coalition, and previously served as the Board Co-Chair of African Services Committee, an organization providing health and human services to 7000 African immigrants living in the New York region.

Sam's background includes a Masters in Public Health at Columbia University (1994), two years as a U.S. Peace Corps volunteer in the Central African Republic (1989-91) and studies in Arabic and Economics at the University of London (1985-86).

e-mail: savrett@earthlink.net



Ian McGowan, M.D., Ph.D. FRCP

Ian McGowan is a recognized authority on the development of microbicides, substances designed to prevent the sexual transmission of HIV and other sexually transmitted infections when applied topically to the vagina or rectum. In addition, he has extensive industry experience and knowledge of domestic and international project management, including regulatory aspects of drug development, and has served as a consultant for the U.S. Centers for Disease Control and Prevention and the World Health Organization. He is also a member of the US Food and Drug Administration (FDA) Antiviral Advisory Committee.

Dr. McGowan obtained his medical degree from the University of Liverpool in the United Kingdom, where he also completed postgraduate training in internal medicine, infectious diseases, and gastroenterology. He obtained his PhD in immunology from Oxford University and undertook post-doctoral research at UCLA. Between 1997 and 2002, Dr. McGowan held a number of senior positions in the pharmaceutical industry. While Director of research at Gilead Sciences, he was responsible for the Phase II/III clinical development of the antiretroviral drug tenofovir disoproxil fumarate (Viread).

Dr. McGowan is co-principal investigator of the University of Pittsburgh-based Microbicide Trials Network (MTN), an HIV/AIDS clinical trials network established in 2006 by the National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes of Health. In this capacity, Dr. McGowan is intimately involved in the oversight and leadership of a major global effort that brings together international investigators and community and industry partners who are focused on clinical research to support licensure of topical microbicide products for widespread use. The MTN anticipates conducting 17 scientifically rigorous and ethically sound trials in Africa, India and the United States between 2006 and 2013, including trials designed to evaluate microbicides along with other promising HIV prevention approaches, such as oral antiretroviral prophylaxis.

Dr. McGowan is a Project PI on a NIH-funded "U-19" grant, the Microbicide Development Program, which is undertaking the preclinical and early Phase I development of antiretroviral rectal microbicides. Dr. McGowan is also the PI for a program grant with the University of Oxford to develop aptamers as candidate microbicides for the prevention of HIV, HSV, and HPV infection. Aptamers are sequences of nucleic acid that bind and neutralize viral targets.

Dr. McGowan is currently Professor of Medicine and Co-Director of the Center for Prevention Research at the David Geffen School of Medicine at UCLA, his academic home for the last five years. In September, Dr. McGowan will join the faculty of the University of Pittsburgh School of Medicine as a Professor of Medicine in the Division of Gastroenterology, Hepatology and Nutrition and will hold a joint appointment in the Department of Obstetrics and Gynecology at the Magee-Women's Research Institute.

e-mail: IMcGowan@mednet.ucla.edu

telephone: +1-310-206-3580

Dr. Tony Kelleher

Academic Degrees

MB.BS, UNSW, 1986, PhD, UNSW, 1997

Current Position

Head Immunovirology and Pathogenesis Program
National Centre in HIV Epidemiology and Clinical Research
web: www.webmed.unsw.edu.au/nchecr

Joint Departmental Affiliations

Clinical Immunologist and Immunopathologist, Saint Vincent's Hospital

Research and Professional Experience

- 1986-1992 Internship, Residency and Specialist training in Clinical immunology, St Vincent's Hospital, Sydney, Australia
- 1992 Senior Medical Registrar, St Vincent's Hospital, Sydney, Australia
- 1993 Director of Clinical Training, St Vincent's Hospital, Sydney
- 1993-1997 Research Fellow, Centre for Immunology, and Trainee in Immunopathology, St Vincent's Hospital
- PhD Thesis Title: *Modulation of the Immune response in HIV infection by therapeutic interventions*
- 1997-2000 Post Doctoral Research Fellow and Senior Lecturer, MRC Human Immunology Group, Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, UK
- 2001- Senior Lecturer in Medicine and Group Leader, Laboratory Support Program, National Centre of HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
- 2003- Clinical Academic, HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent's Hospital, Sydney Australia
- 2005- Head, Immunovirology and Pathogenesis Program, National Centre of HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia.
- 2007- NHMRC Practitioner Fellowship

Research Interests:

Immune responses to viral infections. In particular T cell responses to HIV-1 infection. The development of these responses and their impact on viral evolution. The impact of therapy on these responses, >80 peer reviewed publications.

e-mail: t.kelleher@cfi.unsw.edu.au

telephone: + 61 2 8382 3700/2094

Janelle Fawkes

Janelle Fawkes is Manager of Scarlet Alliance, the Australian Sex Workers Association. Scarlet Alliance, formed in 1989 and represents sex workers and community based sex worker organisations at a national level. Through its objectives, policies and programs Scarlet Alliance aims to achieve equality, social, legal, political, cultural, health and economic justice for past and present workers in the sex industry.

Janelles work as a sex work advocate began in the early 1990's as an Executive Committee member of the Western Australian sex worker organisation, SIERA. Janelle has since worked within sex worker organisations and represented sex worker communities on executive boards and steering committees of a variety of organisations, including a two year term as President of Scarlet Alliance and Peer Educator and Peer Services Coordinator roles.

Janelle continues to advocate for the rights of sex workers in the areas of: industrial relations; anti-discrimination law; guidelines for ethical research; legal frameworks that maximise sex workers Occupational Health & Safety; migrant sex workers; the Australian response to trafficking and the invisibility of migrant sex workers; equitable access to protection from law enforcement agencies and within judicial processes; inclusion in the design, development and implementation of sex worker services; and the involvement of sex workers in decision making forums.

Janelle is regularly called upon as an expert on sex industry legislation and its impact on sex worker communities, including invitations to speak at international conferences and a highly acclaimed skills building session for policy makers and program developers at the XVth International AIDs Conference in Thailand.

e-mail: Janelle.fawkes@scarletalliance.org.au
telephone: 02 9326 9455

Associate Professor John Bernard Ziegler

Professor Ziegler was appointed to the senior staff of Sydney Children's Hospital (SCH) in 1974 and to the Faculty of Medicine at University of NSW in 1977. He is Head the Department of Immunology and Infectious Diseases and of the HIV Service, SCH where he is employed as the Senior Staff Specialist in Clinical Immunology, and is Associate Professor of Paediatrics, UNSW. He is an Honorary Consultant Immunologist at the Royal Alexandra Hospital for Children and Honorary Consultant in Paediatrics, The Liverpool Hospital, all in Sydney, NSW Australia. He is a Fellow of the Royal Australasian College of Physicians (RACP) in the Division of Paediatrics and a founding member of the Australasian Society for HIV Medicine (ASHM) and is a member of the Australasian Society for Clinical Immunology & Allergy (ASCIA).

Dr Ziegler graduated in Medicine from the University of Sydney in 1966, gained membership of the RACP in 1969, was awarded MD, UNSW in 1995 and the Graduate Diploma in Higher Education at UNSW in 1998. He trained in Clinical Immunology at St Vincent's Hospital in Sydney and Children's Hospital in Boston and has worked at SCH since completely his fellowship in Boston in 1975. While in Boston his area of research with Drs Fred S. Rosen and Chester A. Alper was the alternative pathway of complement and there contributed to the understanding of the structure and genetics of factor B, and the metabolism of properdin and confirmed the role of factor I *in vivo*.

He was cofounder of ASHM, its first secretary and has served as President. In those capacities he was instrumental, with colleagues, in establishing the scientific meetings of that society which have been held annually since their inception a decade ago. Dr Ziegler is an advocate for children affected by HIV and chairs the KWAIDS ("Kids with AIDS") committee of the AIDS Trust of Australia which has funded family support groups and the annual national camp for families affected by paediatric HIV.

He served on the Immunisation Advisory Committee, NSW Department of Health and is an advocate for childhood immunisation; he also serves on the DOH Anaphylaxis Working Party and the Anaphylaxis Training Steering Committee. He is a member of the ASCIA Anaphylaxis Working Party and its Primary Immunodeficiency Committee. He chairs the Immunoglobulin Users Advisory Group for NSW Health. He serves in the Board of Continuing Professional Development of the RACP.

He has served as consultant on perinatal transmission (breast feeding) of HIV to WHO in Geneva and on management of paediatric HIV in Malaysia and has been a UNICEF consultant on paediatric HIV to Indonesia.

Dr Ziegler regularly lectures on allergy, immunisation, paediatric HIV and primary immunodeficiency in Australia and New Zealand, Malaysia and Indonesia, delivered a paper during the Paediatric HIV Symposium at the 12th World AIDS Conference in Geneva on July 2nd, 1998 and presented at the Durban and Buenos Aires meetings. He is considered the foremost Australian authority on paediatric HIV.

Publications include more than 120 peer reviewed papers, invited papers and book chapters in clinical immunology, rheumatology, HIV medicine, paediatric pain, 14 reports for government and other bodies.

Major contributions in HIV include the first description of mother-to-infant transmission of HIV during breast feeding and the definition of the risk of HIV via breast feeding during maternal seroconversion. Dr Ziegler was instrumental in the setting up of surveillance mechanisms for perinatal exposure to HIV in Australia and has published a description of patterns of perinatal exposure to HIV in Australia. A recent publication confirms the risk associated with breast feeding after an HIV positive pregnancy using data from the entire Australian cohort of perinatally exposed infants.

Current research interests include genetics of congenital immune deficiency disorders, cellular immune responses to viral vaccines, natural history and physiological factors in adolescent chronic fatigue syndrome and epidemiology and diagnosis of severe food allergy in Australian children. HIV research objectives include studies to define the frequency, character and specificity of anti-HIV immune responses present in infants and children exposed perinatally to HIV and genetic and other factors affecting the risk of perinatal transmission. He has compared the methods used in Holocaust denial with those used in attempts to refute a relationship between HIV and AIDS.

e-mail: jziegler@unsw.edu.au

telephone: (02) 9363 2203



Dr. Debrework Zewdie

Director, Global HIV/AIDS Program

Strategic planning, policy guidance and program implementation.
HIV/AIDS, sexually transmitted diseases and reproductive health.

Dr. Debrework Zewdie is the Director of the Global HIV/AIDS Program of the World Bank. Prior to this position she managed the AIDS Campaign Team for Africa (ACTAfrica), and led the team which was responsible for the US\$1 billion Multi-Country HIV/AIDS Program (MAP I and II) for Africa. Dr. Zewdie is the World Bank's UNAIDS Global Coordinator and represents the Bank on the Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria.

Before joining the Bank in 1994, Dr. Zewdie was Deputy Regional Director of the Africa Region for the AIDS Control and Prevention project (AIDSCAP) of Family Health International in Kenya. Previously, Dr. Zewdie held several research, management, and teaching positions focusing on public health issues such as tropical diseases, reproductive health and sexually transmitted diseases, including HIV/AIDS. While in Ethiopia, she was Deputy Director, and later Acting Director, of the National Research Institute of Health. Dr. Zewdie also established and headed the Referral Laboratory for HIV/AIDS in Ethiopia, served as Program Manager of Ethiopia's AIDS/STD Prevention and Control Program, and taught immunology to medical students at Addis Ababa University.

She received her Ph.D. in Immunology from the University of London and was a Senior MacArthur Fellow at Harvard University's School of Population and Development Studies. Dr. Zewdie has been published in over 100 journals and book chapters on a variety of subjects.

e-mail: dzewdie@worldbank.org

telephone: (202) 473-9414



Dr. Mark A. Wainberg

Dr. Mark A. Wainberg is Director of Research at the Jewish General Hospital as well as Professor of Medicine and Microbiology and Immunology at McGill University in Montreal, Canada, where he also serves as Director of the McGill University AIDS Centre. Dr. Wainberg is an internationally recognized scientist in the field of HIV/AIDS. He served as President of the International AIDS Society between 1998-2000 with responsibilities that included organization of the XIIIth International Congress on AIDS in Durban, South Africa, 2000. Dr. Wainberg is proud of the role that he played in the choice of South Africa as a venue for this congress, which had an important impact on the issue of access to anti-HIV drugs in developing countries.

He is well-known for his initial identification of 3TC as an anti-viral drug, in collaboration with BioChem Pharma Inc, in 1989, as well as for multiple contributions to the field of HIV drug resistance. His laboratory continues to work in the field of drug development, and, as well, Dr. Wainberg has now turned his attention to novel concepts in prevention of HIV infection in developing countries, such as vaginal microbicides and pre-exposure prophylaxis. He was co-Chair of the XVIth International AIDS Conference that took place in Toronto between August 13-18, 2006. Dr. Wainberg is also a member of numerous international advisory committees in the field of AIDS and is Chair of the Scientific Council of the ANRS (Agence Nationale de Recherche sur le SIDA) (National Agency for AIDS research of France). Dr. Wainberg is an elected fellow of the Royal Society of Canada and is an Officer of the Order of Canada. He is also an Officer of the Ordre National du Québec and is an Honorary Fellow of the Royal College of Physicians and Surgeons of Canada.

Dr. Wainberg is an author of over 400 research papers and 100 reviews and commentary articles that have appeared in the scientific literature, and is the corresponding author on most of these. He also frequently contributes Op-Ed articles on the topic of AIDS to newspapers in Canada and the U.S.A.

e-mail: mark.wainberg@mcgill.ca
telephone:(514) 340-8260

Peter James McDonald

Career Highlights

Establishment of Australian Infectious Diseases Infrastructure and Training.

Identifying the basis for determining optimal dosing schedules for antibiotics in general and especially for prevention of surgical infections. This led to development of a new subsection of the science of pharmacology – pharmacodynamics.

Co - developing the scientific and then clinical assessment of macrolide antibiotics and their world-wide application in the treatment of infectious diseases.

Coordinating international clinical trials in prevention of post operative infections based on pharmacodynamics that resulted in a world-wide reduction of post-operative infections by substantial amounts e.g. in bowel surgery from 40% to 5%.

Co- investigating the causes of pre-term birth and demonstrating strategies that have been applied to reducing premature births

Coordinating the research programme for HIV in Australia that led to a major reduction in AIDS and established Australia as world leader in vaccine development, public health strategies for control of HIV/AIDS and implementing anti-retroviral strategies.

Promoting strategies of rapidly applying research findings into policy and practice.

Leading health services research around the most effective health systems for Australia

CURRENT POSITION AND AFFILIATIONS

Retired from Flinders University and awarded Emeritus status 2003. Continuing as Professorial Fellow for National Centre for HIV Epidemiology and Clinical Research (NCHECR), University of New South Wales.

e-mail: phtmcdonald@bigpond.com

telephone: (61) (0) 88563 962



Ruth Pollard

Ruth is a reporter on the investigations team at The Sydney Morning Herald, after just finishing a four-year stint as the paper's health reporter. She has been at the Herald for the past eight years, and before that has worked for the Australian Federation of AIDS Organisations, Australian Associated Press, Social Change Media and the Sydney Star Observer.

A journalist for 17 years, Ruth is media president of the Media, Entertainment and Arts Alliance - the union that represents journalists, actors and technicians in Australia - and is also president of the NSW Journalist's Benevolent Fund and HIV advisor to the International Federation of Journalists.

In 2004 Ruth was a finalist in the feature writing category of the Walkley Awards for Excellence in Journalism and in 2006 she received a fellowship from the Asia Pacific Media Foundation (sorry I have to check it's correct title) examining politics, religion and social issues in Indonesia and Malaysia.

She has edited two media guides on the reporting of HIV/AIDS - one for the Australian Federation of AIDS Organisations, published in 2002 and the other for the International Federation of Journalists, published in 2006.

e-mail: rpollard@smh.com.au



Craig McClure

Craig McClure has been the Executive Director of the International AIDS Society (IAS), the world's leading independent association of HIV professionals since 2004.

Craig has a background in political science, international relations, education and counseling. He has worked in the field of HIV/AIDS for 15 years, primarily in the areas of policy, advocacy and education.

In 2003-2004 he played a central role at the World Health Organisation (WHO) headquarters as a member of the coordination team for the development of the "3 by 5" strategy – WHO and the Joint United Nations Programme on HIV/AIDS (UNAIDS) initiative to expand ARV treatment access for people living with HIV/AIDS in resource-limited settings.

Prior to working with WHO, Craig worked for the International AIDS Vaccine Initiative (IAVI), focusing on mobilizing public sector support for vaccine research, as well as working on policy development in vaccine research and access.

As a founding partner of the consultancy Health Hounds, Craig led a number of HIV/AIDS policy and programme development projects for intergovernmental, governmental, non-governmental and corporate sector clients during 1997-2000.

Prior to 1997, Craig worked for four years for the Canadian Treatment Information Exchange, a non-governmental organization focused on HIV treatment information, education and advocacy.

Craig has published and presented on his HIV work at international, regional and national conferences over the past 15 years. He is committed to approaches to ending the epidemic that balance the need for further research with expanded implementation of existing prevention tools, ethical and equitable access to care and treatment, and an end to stigma and discrimination against people living with HIV/AIDS and the marginalized communities that remain most vulnerable to HIV infection.

e-mail: karen.bennett@iasociety.org

Karen Bennett

Karen Bennett is the Communications Manager for the International AIDS Societies and its conferences. She began working in HIV/AIDS as head of communications for the 13th International AIDS Conference in her home town of Durban, South Africa in 2000, and followed this with the same position at the next International AIDS Conference in Barcelona in 2002. Following the Barcelona conference, Karen returned to South Africa with her family, where she worked as a consultant for numerous HIV- and health-related organizations and events. She rejoined the IAS in January 2006.

Karen holds degrees in public relations and medical technology.

e-mail: karen.bennett@iasociety.org

Simon Noble

Editor, *IAVI Report*, International AIDS Vaccine Initiative (2003 – Present)

Director-level position. Leader of IAVI Report unit with overall responsibility for a four-person team that compiles public-health periodicals covering the AIDS vaccine research field and associated disciplines for print publication and distribution. Responsible for overseeing all aspects of publications—from conceptualization of articles to writing, editing, layout, design, and printing—and managing day to day activities, as well as long-range planning and maintaining a good grasp of where the AIDS vaccine field is headed, which requires maintaining close professional relationships with a multitude of scientific leaders in HIV/AIDS, including those at the forefront of immunological and virological research and science political leaders.

IAVI Report is an international print magazine that covers cutting-edge AIDS vaccine research and related topics, and features interviews with and articles from scientific and political leaders in the global fight against HIV/AIDS. It is distributed to more than 12,000 subscribers in 140 countries worldwide. Since 2005, *IAVI Report* has been indexed by PubMed and MEDLINE, the National Library of Medicine's (part of the US National Institutes for Health) principal online bibliographic citation database of the world's biomedical literature. Publications are selected for inclusion by the Director of the National Library of Medicine based on scientific quality.

Launched in October 2003, *VAX* is a more accessible non-technical, community-oriented bulletin that explains scientific concepts around AIDS vaccine trials and is particularly popular in developing countries and at clinical trial sites. *VAX* is translated from English into Spanish, French, German, and Portuguese; Thai and Chinese Mandarin language versions are under consideration. Diverse distribution networks have been set up in many countries in alliance with local non-governmental organizations, and part of the Editor's role is to foster these distribution relationships to fulfill our public health role. Important examples of diverse distribution networks are in Brazil, Spain, and South and Latin America.

The website *IAVI Report Online* hosts each issue of the print publications in HTML format and also incorporates many other features, including daily news headlines and research journal highlights. The site attracts 30,000 visitors each month. The website also hosts the IAVI Database of AIDS Vaccines in Human Trials, the definitive resource worldwide that comprehensively lists all of the AIDS vaccine trials, past and present.

The publications from the IAVI Report unit formed the basis of a US\$2 million funding application from the Dutch Government. It was successfully granted at the end of October 2006.

In 2007, I created the IAVI Report Travel Awards to provide financial support to enable four scientists from developing countries severely affected by HIV/AIDS to attend the Keystone Symposia on Molecular and Cellular Biology.

e-mail: snoble@iavi.org
telephone: (917) 981 4102

Kirketon Road Centre

Level 1, 100 Darlinghurst Road, Kings Cross

Tel: 61 2 9360 2766

Fax: 61 2 9360 5154

The Kirketon Road Centre (KRC) was established in April 1987 as a NSW State Government initiative following recommendations of the Parliamentary Select Committee on Prostitution in NSW (Rogan Report 1986). The aims of the service are:

1. To prevent and minimise HIV/AIDS and other transmissible infections (including sexually transmissible infections and hepatitides) among 'at risk' youth, sex workers and injecting drug users.
2. To treat and care for clients with HIV/AIDS and other transmissible infections among these target populations.

KRC provides medical, nursing, counselling and social welfare services. KRC also operates comprehensive needle/syringe, Outreach and methadone access programs.

Services provided include:

- assessment and management of general health issues
- sexual health screening, treatment of sexually transmissible infections and sex worker 'check ups'
- HIV antibody testing, pre and post test counselling
- primary care of HIV infection and AIDS related conditions, with access to antiretroviral therapies and clinical trials
- hepatitis A and B screening and vaccination
- hepatitis C screening and monitoring of liver function
- specialist medical clinics
- women's health checks including pap smears and breast examination
- family planning advice, contraception, pregnancy testing, counselling and referral
- medical and psychosocial assessment of transgender issues and specialist referral
- dental assessment clinics
- drug and alcohol counselling, referral to drug detoxification, treatment and rehabilitation programs
- methadone access program and referral
- crisis and ongoing counselling for emotional issues
- social welfare information, eg. housing, income, education and legal information
- needle syringe program
- outreach program